

REVISION OF THE MONOGRAPH ON ETHINYLESTRADIOL

(ETHINYLESTRADIOLUM)

Draft proposal for inclusion in *The International Pharmacopoeia*

(December 2018)

DRAFT FOR COMMENTS

Please send any comments you may have on the attached text to Dr Herbert Schmidt, Technical Officer, Medicines Quality Assurance, Technologies Standards and Norms (<u>schmidth@who.int</u>), with a copy to Ms Sinead Jones (<u>jonessi@who.int</u>) by **28 February 2019**.

Medicines Quality Assurance working documents will only be sent out electronically and will also be placed on the Medicines website for comment under "Current projects". If you have not already received our draft working documents, please send your email address to jonessi@who.int and we will add your name to our electronic mailing list.

© World Health Organization 2018

All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and member organizations) without the permission of the World Health Organization. The draft should not be displayed on any website.

Please send any request for permission to:

Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies Standards and Norms, Regulation of Medicines and other Health Technologies, Department of Essential Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland, fax: (41 22) 791 4856, email: <u>kopps@who.int</u>.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.

28 29 30

31

32 33 34

35

36 37

38 39

40

41

42

43 44

45

46

47 48

49

50

51

52 53

54

1 2

3

4

5

6

SCHEDULE FOR THE PROPOSED ADOPTION PROCESS OF DOCUMENT QAS/18.781: Draft proposal for inclusion in *The International Pharmacopoeia* REVISION OF THE MONOGRAPH ON ETHINYLESTRADIOL (ETHINYLESTRADIOLUM)

Revision or the monograph prepared.	September 2018
Presentation to the WHO Expert Committee on Specifications for Pharmaceutical Preparations.	October 2018
Draft revision sent out for public consultation	December 2018 – February 2019
Further follow-up action as required.	

61

62 [Note from the Secretariat. It is proposed to revise the monograph on Ethinylestradiol as follows:
63

- *Replace the existing TLC method to test for related substances with an HPLC method.*
- *Add an alternative assay method.*
- Add an alternative identity test C by HPLC and revise the identity test B by TLC.
- Add a transparency list to the monograph.
- 68

69 The proposed changes are based on information found in the European Pharmacopoeia and in

- 70 Kommentar zum Europäischen Arzneibuch, Gesamtwerk mit 53. Aktualisierungslieferung 2016,
- 71 Wissenschaftliche Verlagsgesellschaft Stuttgart.
- 72

73 *Changes from the current monograph are indicated in the text by insert or delete.*]

- 74
- 75 76
- 77

78	Draft proposal for inclusion in The International Pharmacopoeia
79	REVISION OF THE MONOGRAPH ON
80	ETHINYLESTRADIOL
81	(ETHINYLESTRADIOLUM)
82	
83	Ethinylestradiol (Ethinylestradiolum)
84	
85	Molecular formula. C ₂₀ H ₂₄ O ₂
86	
87	Relative molecular mass. 296.4
88	
89	Graphic formula.
90	
91	
92	
93	Chemical name. 19-Nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol ; 17-ethynyl-estra-
94	$\frac{1,3,5,(10)}{1,3,5,(10)}$ triene $\frac{3,17\beta}{1,3,5}$ diol; CAS Reg. No. 57-63-6.
95	
96	Description. A white to slightly yellowish white, crystalline powder; odourless.
97	
98	Solubility. Practically insoluble in water; freely soluble in ethanol (~750 g/l) TS; soluble in
99	acetone R, and dioxan R and dilute alkaline solutions.
100	
101	Category. Estrogen.
102	
103	Storage. Ethinylestradiol should be kept in a well-closed container, protected from light.
104	
105	Additional information. Ethinylestradiol may exhibit polymorphism. may exist in 2
106	polymorphic forms one of which melts at about 183°C, the other, metastable, at about 143°C.
107	

Requirements 108 109 Definition. Ethinylestradiol contains not less than 97.597.0% and not more than 102.0% of 110 $C_{20}H_{24}O_2$, calculated with reference to the dried substance. 111 112 **Identity tests** 113 114 Either test A or tests B and C may be applied. 115 • 116 A. Carry out the examination as described under <u>1.7 Spectrophotometry in the infrared region</u>. 117 The infrared absorption spectrum is concordant with the spectrum obtained from 118 ethinylestradiol RS or with the reference spectrum of ethinylestradiol. 119 120 If the spectrum thus obtained are not concordant, repeat the test using the residues obtained 121 by separately dissolving the test substance and ethinylestradiol RS in a small amount of 122 methanol R and evaporating to dryness. The infrared absorption spectrum is concordant 123 with the spectrum obtained from ethinylestradiol RS. If the spectrum obtained from the solid 124 state of the test substance is not concordant with the spectrum obtained from the reference 125 126 substance, compare the spectra of solutions in chloroform R containing 30 mg/mL, using a 127 path length of 0.2 mm. 128 B. Carry out the test as described under 1.14.1 Thin-layer chromatography using silica gel R1 129 as the coating substance and a mixture of 10 volume of dehydrated ethanol R and 90 130 volumes of toluene R as the mobile phase. Apply separately to the plate 5 μ L of each of two 131 solutions in a mixture of 10 volumes of methanol R and 90 volumes of dichloromethane R 132 containing (A) 1.0 mg of the test substance per mL, and (B) 1.0 mg of ethinylestradiol RS 133 per mL. Develop the plate for a distance of 15 cm. After removing the plate from the 134 chromatographic chamber, allow it to air dry until the solvents have evaporated, heat at 135 110 °C for 10 minutes, spray the hot plate with sulfuric acid/ethanol (20%) TS and heat 136 again at 110 °C for 10 minutes. Allow to cool and examine the chromatogram in daylight 137 and in ultraviolet light (365 nm). The principal spot obtained with solution (A) corresponds 138 in position, appearance, and intensity with that obtained with solution (B). Carry out the test 139 as described under 1.14.1 Thin-layer chromatography, using kieselguhr R1 as the coating 140

141	substance and a mixture of 1 volume of propylene glycol R and 9 volumes of acetone R to
142	impregnate the plate, dipping it about 5 mm beneath the surface of the liquid. After the
143	solvent has reached a height of at least 16 cm, remove the plate from the chromatographic
144	chamber and allow it to stand at room temperature until the solvent has completely
145	evaporated. Use the impregnated plate within 2 hours, carrying out the chromatography in
146	the same direction as the impregnation. Use toluene R as the mobile phase. Apply separately
147	to the plate 2 μ L of each of 2 solutions in a mixture of 9 volumes of chloroform R and 1
148	volume of methanol R containing (A) 1.0 mg of the test substance per mL, and (B) 1.0 mg
149	of ethinylestradiol RS per mL. Develop the plate for a distance of 15 cm. After removing the
150	plate from the chromatographic chamber, allow it to dry in air until the solvents have
151	evaporated, heat at 120°C for 15 minutes, spray with 4-toluenesulfonic acid/ethanol TS, and
152	then heat at 120°C for 5-10 minutes. Allow to cool, and examine the chromatogram in
153	daylight and in ultraviolet light (365 nm). The principal spot obtained with solution A
154	corresponds in position, appearance, and intensity with that obtained with solution B.
155	
156	C. Carry out the test as described under 1.14.4 High-performance liquid chromatography using
157	the conditions and solutions given under "Assay", Method A. The retention time of the
158	principal peak in the chromatogram obtained with solution (1) corresponds to the retention
159	time of the peak due to ethinylestradiol in the chromatogram obtained with solution (5).
160	
161	Specific optical rotation. Use a 4.0 mg/mL solution in pyridine R and calculate with reference to
162	the dried substance; $\left[\alpha\right]_{D}^{20^{\circ}C} = -27.0^{\circ}$ to -30.0° .
163	
164	Loss on drying. Dry to constant weight at 105°C; it loses not more than 10 mg/g.
165	
166	Related substances. Carry out the test as described under 1.14.4 High-performance liquid
167	<i>chromatography</i> , using a stainless steel column (25 cm \times 4.6 mm) packed with end-capped
168	particles of silica gel, the surface of which has been modified with chemically-bonded butylsilyl
169	<u>groups (5 μm).</u>
170	
171	Use the following conditions for gradient elution:
172	
173	mobile phase A: 30 volumes of acetonitrile for chromatography R and 70 volumes of water R;

175 mobile phase B: 25 volumes of water R and 75 volumes of acetonitrile for chromatography R.

176

174

177

Time	Mobile phase	Mobile phase	Comments
(minutes)	<u>A</u>	<u>B</u>	
	<u>(% v/v)</u>	<u>(% v/v)</u>	
<u>0–35</u>	<u>100</u>	<u>0</u>	<u>Isocratic</u>
35-65	<u>100 to 0</u>	<u>0 to 100</u>	Linear gradient
<u>65–66</u>	<u>0 to 100</u>	<u>100 to 0</u>	Return to initial
			<u>composition</u>
<u>66–75</u>	<u>100</u>	<u>0</u>	Re-equilibration

178

179 Prepare the following solutions using a mixture of 40 volumes of water R and 60 volumes of

180 <u>acetonitrile R as diluent</u>. For solution (1), dissolve 50.0 mg of the test substance in 30 mL of

181 acetonitrile and dilute to 50.0 mL. For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL.

182 Dilute 1.0 mL of this solution to 10.0 mL. For solution (3), dissolve 2 mg of estrone R (impurity

183 <u>C) in 10.0 mL. Dilute 1.0 mL of this solution to 100.0 mL. For solution (4), dissolve the content</u>

184 of a vial of ethinylestradiol for system suitability RS (containing ethinylestradiol and the

185 <u>impurities B, F, H, I and K) in 1.0 mL of solution (3).</u>

186

187 Operate with a flow rate of 1.5 mL per minute. As a detector, use an ultraviolet

188 spectrophotometer set at a wavelength of 220 nm. Maintain the column temperature at 30 °C.

189 Inject alternatively 30 μ L each of solution (1), (2) and (4) and record the chromatograms.

190

191 Use the chromatogram obtained with solution (4) and the chromatogram supplied with

192 ethinylestradiol for system suitability RS to identify the peaks due to the impurities B, C, F, H, I

and K. The impurities, if present, are eluted at the following relative retention with reference to

194 <u>ethinylestradiol (retention time about 35 min): impurity F about 0.2; impurity H about 0.5;</u>

195 <u>impurity I about 0.8; impurity B about 0.88; impurity C about 0.92; impurity K about 1.3.</u>

196


197 The test is not valid unless in the chromatogram obtained with solution (4) the resolution between
198 the peaks due to impurity I and B is at least 1.2.

199		
200	In the	chromatogram obtained with solution (1):
201		
202	•	the area of any peak corresponding to impurity B, when multiplied by a correction factor
203		of 0.7, is not greater than five times the area of the peak due to ethinylestradiol in the
204		chromatogram obtained with solution (2) (0.5 %);
205		
206	•	the area of any peak corresponding to impurity I, when multiplied by a correction factor of
207		0.4, is not greater than twice the area of the peak due to ethinylestradiol in the
208		chromatogram obtained with solution (2) (0.2 %);
209		
210	•	the area of any peak corresponding to impurity H or K is not greater than twice the area of
211		the peak due to ethinylestradiol in the chromatogram obtained with solution (2) (0.2 %);
212		
213	•	the area of any peak corresponding to impurity C or F is not greater than 1.5 times the area
214		of the peak due to ethinylestradiol in the chromatogram obtained with solution (2) (0.15
215		<u>%);</u>
216		
217	•	the area of any other impurity peak is not greater than the area of the peak due to
218		ethinylestradiol in the chromatogram obtained with solution (2) (0.10 %);
219		
220	•	the sum of the corrected areas of any peak corresponding to impurity B and I and the areas
221		of all other impurity peaks is not greater than eight times the area of the peak due to
222		ethinylestradiol in the chromatogram obtained with solution (2) (0.8 %). Disregard any
223		peak with an area less than 0.5 times the area of the peak due to ethinylestradiol in the
224		chromatogram obtained with solution (2) (0.05 %).
225		
226	Estroi	ie. Carry out the test as described under <u>1.14.1 Thin-layer chromatography</u> , using silica gel
227	R1 as i	the coating substance and a mixture of 92 volumes of dichloroethane R, 8 volumes of
228	metha	nol R, and 0.5 volumes of water as the mobile phase. Apply separately to the plate 5 μ l of
229	each o	f 2 freshly prepared solutions in a mixture of 9 volumes of chloroform R and 1 volume of
230	metha	nol R containing (A) 20 mg of the test substance per mL, and (B) 0.20 mg of estrone RS per
231	mL. A	fter removing the plate from the chromatographic chamber, allow it to dry in air until the


232	odour of the solvent is no longer detectable; then heat at 110°C for 10 minutes. Spray the hot plate			
233	with	with sulfuric acid/ethanol TS, heat again at 110°C for 10 minutes, and examine the chromatogram		
234	in u	in ultraviolet light (365 nm). The spot obtained with solution B is more intense than any spot,		
235	corresponding in position and appearance, obtained with solution A.			
236				
237	Ass	ay		
238				
239	•	Either method A or method B may be applied.		
240				
241	<u>A.</u>	Carry out the test as described under 1.14.4 High-performance liquid chromatography,		
242		using the conditions given below under "Related substances".		
243				
244		Use solution (1) as described under "Related substances". Prepare the following additional		
245		solution: for solution (5), dissolve 50.0 mg of ethinylestradiol RS in 30 mL of acetonitrile R		
246		and dilute to 50.0 mL with water R.		
247				
248		Inject alternately 50 μ L each of solution (1) and (5) and record the chromatograms.		
249				
250		Measure the areas of the peaks corresponding to ethinylestradiol obtained in the		
251		chromatograms of solutions (1) and (5) and calculate the percentage content of		
252		ethinylestradiol ($C_{20}H_{24}O_2$) using the declared content of $C_{20}H_{24}O_2$ in ethinylestradiol RS.		
253				
254	<u>B.</u>	Dissolve 50.0 mg of the test substance in sufficient dehydrated ethanol R and dilute to 100.0		
255		mL with the same solvent. Dilute 10.0 mL of this solution to 50.0 mL with the same solvent.		
256				
257		Measure the absorbance of a 1 cm layer of the diluted solution at the maximum at about 281		
258		nm. Calculate the percentage content of ethinylestradiol ($C_{20}H_{24}O_2$) using the absorptivity		
259		value of 7.1 $(A_{1 cm}^{1 \%} = 71)$		
260				
261		Dissolve about 0.05 g, accurately weighed, in sufficient dehydrated ethanol R to produce		
262		100 mL, and dilute 10.0 mL of this solution to 50.0 mL with the same solvent. Measure the		
263		absorbance of a 1-cm layer of the diluted solution at the maximum at about 281 nm.		
264		Calculate the amount of $C_{20}H_{24}O_2$ in the substance being tested by comparison		

- 265 with ethinylestradiol RS, similarly and concurrently examined. In an adequately calibrated
- 266 spectrophotometer the absorbance of the reference solution should be 0.72 ± 0.04 .
- 267


268 Impurities




280 product)



294



- 296 (degradation product)
- 297



Working document QAS/18.781 Page 12

